CERS - Cerus Corporation
Cerus' Q1 2026 product revenues grew another 24% YoY. This was mainly thanks to strong platelet demand and rapid IFC adoption. Management raised its 2026 product revenue guidance to $227-$231 million, which would imply promising 10%-12% YoY growth. IFC volumes rose about 120% YoY, making it the clearest current growth vertical beyond platelets.
Cerus Corporation (CERS) Q1 2026 Earnings Call Transcript
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the first quarter ended March 31, 2026, and provided a business update. “We delivered a strong start to 2026, with first quarter performance driven by strength across our business, in particular by increasing demand for our INTERCEPT Fibrinogen Complex,” said William “Obi” Greenman, Cerus' president and chief executive officer. “As a result, we are raising our product revenue guidance for th.
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the signing of a new, four-year supply agreement with Établissement Français du Sang (EFS), the French Blood Establishment, for the INTERCEPT Blood System. The agreement covers the INTERCEPT Blood System for platelets and plasma as well as the next generation, LED-based INT200 illumination device. “We are proud to announce a new four-year supply agreement with the French Blood Establishment,” said Christian Boute.
Cerus (NASDAQ: CERS - Get Free Report) and Akanda (NASDAQ: AKAN - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends. Profitability This table compares Cerus and Akanda's net margins,
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2026 financial results will be released on Thursday, April 30, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the.
Cerus Corporation (NASDAQ: CERS - Get Free Report) CFO Kevin Dennis Green sold 127,544 shares of the company's stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $1.66, for a total value of $211,723.04. Following the sale, the chief financial officer owned 1,040,551 shares in the company, valued
Cerus Corporation (NASDAQ: CERS - Get Free Report) COO Vivek Jayaraman sold 165,200 shares of the stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $1.66, for a total value of $274,232.00. Following the sale, the chief operating officer owned 1,747,674 shares of the company's stock, valued at
Cerus Corporation (NASDAQ: CERS - Get Free Report) insider Chrystal Jensen sold 113,008 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $1.66, for a total value of $187,593.28. Following the transaction, the insider owned 946,131 shares of the company's stock, valued at
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that Vivek Jayaraman, Cerus' chief operating officer, will be promoted to president and chief executive officer, effective July 1, 2026. William “Obi” Greenman will become executive chairman of the board of directors. At the time of his appointment, Mr. Jayaraman will join the Board of Directors. “Following a thorough succession planning process, this transition represents a natural step as we prepare for the nex.
Cerus (NASDAQ: CERS) executives used a presentation and fireside chat at the TD Cowen Healthcare Conference to reiterate the company's focus on making its INTERCEPT Blood System a global standard of care for transfusion medicine, while outlining commercial priorities across U.S. platelets, international expansion, and the company's INTERCEPT Fibrinogen Complex (IFC) franchise. Chairman, President and CEO
CERS' INTERCEPT platform (kits + illuminators) is scaling globally, with record 2025 results. They've also grown their adoption across ~40 countries. INT200 received European approval and launched. They also have a US PMA filing targeted for 2026. This means CERS may soon have another hardware refresh cycle, with future kit pull-through.
Cerus Corporation (CERS) Q4 2025 Earnings Call Transcript
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for its full year and fourth quarter ended December 31, 2025. “Our strong 2025 results reflect our disciplined execution, as we continued to deliver on our mission of safeguarding the world's blood supply. This past year, we achieved our highest annual kit shipments, enabling an estimated 600,000 patients worldwide to receive INTERCEPT-treated blood components,” said William “Obi” Greenman, Ceru.
Cerus Corporation (NASDAQ: CERS - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $1.81 and traded as high as $2.61. Cerus shares last traded at $2.56, with a volume of 2,004,835 shares traded. Analyst Ratings Changes
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that members of the Company's management are scheduled to present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 10:30 a.m. EST. A live webcast of the fireside chat will be accessible through the Investor Relations page of the Cerus website at http://www.cerus.com/ir. A replay will be available for 90 days after the event. ABOUT CERUS Cerus Corporation is dedicated solely to safe.
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today its fourth quarter and full-year 2025 financial results will be released on Monday, March 2, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor.
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced the start of the INITIATE study by the German Red Cross Blood Donation Service Baden-Württemberg – Hessen and its subsidiary organization, the German Red Cross Blood Donation Service North-East. The prospective, multicenter, non-interventional safety study, sponsored by DRK Blood Donation Service Baden-Württemberg-Hessen, is the first of its kind in Germany to evaluate the routine use of pathogen-inactivated plat.